Pharmacological chaperone therapy for Gaucher disease: a patent review

Bibliography

• Barrange JA, Cabrera-Salazar MA. Lysosomal storage disorders. Springer, NY; 2007
   Google Scholar
• Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 2004;5:554-65
   PubMed Web of Science ®Google Scholar
• Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009;1:268-79
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Fietz MJ, Hopwood JJ. Diagnosis of lysosomal storage disorders: current techniques and future directions. Expert Rev Mol Diagn 2004;4:677-91
   PubMed Web of Science ®Google Scholar
• Wennekes T, van den Berg RJBHN, Boot RG, Glycosphingolipids–Nature, function, and pharmacological modulation. Angew Chem Int Ed 2009;48:8848-69
   PubMed Web of Science ®Google Scholar
• Hers HG. alpha-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem J 1963;86:11-16
   PubMed Web of Science ®Google Scholar
• De Duve C, Pressman BC, Gianetto R, Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 1955;60:604-17
   PubMed Web of Science ®Google Scholar
• Pastores GM. Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospects. Expert Opin Ther Pat 2003;13:1157-72
   Web of Science ®Google Scholar
• Smid BE, Aerts JMFG, Boot RG, Pharmacological small molecules for the treatment of lysosomal storage disorders. Expert Opin Invest Drug 2010;19:1367-79
   PubMed Web of Science ®Google Scholar
• Bernier V, Lagace M, Bichet DG, Bouvier M. Pharmacological chaperones: potential treatment for conformational disease. Trends Endocrinol Metabol 2004;15:5
   Google Scholar
• Coehn FE, Kelly JW. Therapeutic approaches to protein misfolding diseases. Nature 2003;426:905-9
   PubMedGoogle Scholar
• Grabowski GA, Kolodny EH, Weinreb NJ, Gaucher disease: phenotypic and genetic variation, Chapter 146.1. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular bases of inherited disease. McGraw-Hill, NY; 2006. Available from: http://genetics.accessmedicine.com [Last accessed 11th February 2011]
   Google Scholar
• Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Ann Rev Biochem 1992;61:307-30
   PubMed Web of Science ®Google Scholar
• Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002;49:359-78
   PubMedGoogle Scholar
• MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24:s13-14; discussion 11-2
   PubMedGoogle Scholar
• Pastores GM, Weinreb NJ, Aerts H, Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:s4-s14
   PubMed Web of Science ®Google Scholar
• Gaucher PCE. De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie [academic thesis]. Paris, France; 1882
   Google Scholar
• Beutler E, Grabowski GA. Glucosylceramide lipidosis–Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular bases of inherited diseases. 8th edition. McGraw-Hill, NY; 2001. p. 3635-68
   Google Scholar
• Zeller JL, Burke AE, Glass RM. Gaucher disease. JAMA 2007;298:1358
   PubMedGoogle Scholar
• Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 2004;83:6-15
   PubMed Web of Science ®Google Scholar
• Raghavan SS, Topol J, Kolodny EH. Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet 1980;32:158-73
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372:1263-71
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 2005;35:355-64
   PubMedGoogle Scholar
• Hruska KS, LaMarca, ME, Sidransky E. Gaucher disease: molecular biology and genotype-phenotype correlations. In: Futerman AH, Zimran A, editors, Gaucher disease. Taylor & Francis, Boca Raton; 2006. p. 13-48
   Google Scholar
• Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation polymorphism spectrum in the glucorebrosidase gene (GBA). Hum Mutat 2008;29:567-83
   PubMed Web of Science ®Google Scholar
• Dvir H, Harel M, McCarthy AA, X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 2003;4:704-9
   PubMed Web of Science ®Google Scholar
• Zuckerman S, Lahad A, Shmueli A, Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA 2007;298:1281-90
   PubMed Web of Science ®Google Scholar
• Sobera LA, Sundaravinayagan D, Dulsat C, Rosa E. Therapeutic targets for Gaucher's disease. Drug Future 2009;34:1001-4
   Google Scholar
• Zimran A, Altarescu G, Phillips M, Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010;115:4651-6
   PubMed Web of Science ®Google Scholar
• Available from: www.news-medical.net/news/20100712/FDA-accepts-Protalixs-taliglucerase-alfa-NDA-assigns-PDUFA-action-date.aspx [Last accessed 11th Februrary 2011]
   Google Scholar
• Biomarin pipeline: GALNS for MPS IVA (Morquio A disease). Available from: www.bmrn.com/pipeline/morquio-syndrome.php [Last accessed 11th February 2011]
   Google Scholar
• Shire pipeline. Available from: www.shire.com/shireplc/en/rd/pipeline [Last accessed 11th February 2011]
   Google Scholar
• Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr Suppl 2008;97:88-93
   Google Scholar
• Shukla GS, Shukla A, Radin NS. Gangliosides inhibit glucosylceramide synthase: a possible role in ganglioside therapy. J Neurochem 1991;56:2125-32
   PubMed Web of Science ®Google Scholar
• Platt FM, Jeyakumar M, Andersson U, Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 2001;24:275-90
   PubMed Web of Science ®Google Scholar
• Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconjugate J 1996;13:153-7
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Fitzgibbon EJ, Harris C, Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol 2008;64:514-22
   PubMed Web of Science ®Google Scholar
• Cox T, Lachman R, Hollak C, Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5
   PubMed Web of Science ®Google Scholar
• Platt FM, Butters TD, Barranger JA. Substrate reduction therapy. In: Barranger JA, Cabrera-Salazar MA, editors, Lysosomal storage disorders. Springer, NY; 2007. p. 153-68
   Google Scholar
• Cabrera-Salazar MA, Novelli E, Barranger JA. Gene therapy for the lysosomal storage disorders. Curr Opin Mol Ther 2002;4:349-58
   PubMed Web of Science ®Google Scholar
• Sands MS. Gene therapy. In: Platt FM, Walkley SU, editors, Lysosomal disorders of the brain. Oxford University Press, Oxford; 2004. p. 409-30
   Google Scholar
• Snyder EY, Daley GQ, Goodell M. Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system. J Neurosci Res 2004;76:157-68
   PubMedGoogle Scholar
• Lee JP, Clark D, Jeyakumar M, Neural stem cell therapy in lysosomal storage disorders. In: Barrange JA, Cabrera-Salazar MA, editors, Lysosomal storage disorders. Springer, NY; 2007. p. 197-216
   Google Scholar
• Ringden O, Groth CG, Erikson A, Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 1995;59:864-70
   PubMed Web of Science ®Google Scholar
• Pollack A. FDA halts 27 gene therapy trials after illness: leukemia-like cases in 2 children in France prompt the action. NY Times (print) 2003:A1, 17
   Google Scholar
• Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003;299:320
   PubMed Web of Science ®Google Scholar
• Bonetta L. Leukemia case triggers tighter gene-therapy controls. Nat Med 2002;8:1189
   PubMed Web of Science ®Google Scholar
• Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5:112-15
   PubMed Web of Science ®Google Scholar
• Fan JQ. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 2007;389:1-11
   Google Scholar
• Suzuki Y, Ichinomiya S, Kurosawa M, Chemical chaperone therapy: clinical effect in murine GM1-gangliosidosis. Ann Neurol 2007;62:671-5
   PubMed Web of Science ®Google Scholar
• Fan JQ, Ishii S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J 2007;274:4962-71
   PubMed Web of Science ®Google Scholar
• Porto C, Cardone M, Fontana F, The Pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 2009;17:964-71
   PubMed Web of Science ®Google Scholar
• Yu Z, Sawkar AR, Kelly JW. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J 2007;274:4944-5017
   PubMed Web of Science ®Google Scholar
• Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 2007;37:298-314
   PubMed Web of Science ®Google Scholar
• Benjamin ER, Flanagan JJ, Schilling A, The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis 2009;32:424-40
   PubMed Web of Science ®Google Scholar
• Wang X, Koulov AV, Kellner WA, Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic 2008;9:1878-93
   PubMedGoogle Scholar
• Becq F. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis. Drugs 2010;70:241-59
   PubMed Web of Science ®Google Scholar
• Sanchez-Olle G, Duque J, Egido-Gabas M, Promising results of the chaperone effect caused by iminosugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cell Mol Dis 2009;42:159-66
   PubMed Web of Science ®Google Scholar
• Fan JQ. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 2003;24:355-60
   PubMed Web of Science ®Google Scholar
• Stuzt AE. Iminosugars as glycosidase inhibitors. Wiley-VCH, Weinheim; 1999
   Google Scholar
• Compain P, Martin OR. Iminosugars: from synthesis to therapeutic applications. Wiley-VCH, Weinheim; 2008
   Google Scholar
• Butters TD. Gaucher disease. Curr Opin Chem Biol 2007;11:412-18
   PubMed Web of Science ®Google Scholar
• Sawkar AR, Adamski-Werner SL, Cheng WC, Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 2005;12:1235-44
   PubMed Web of Science ®Google Scholar
• Sawkar AR, Cheng WC, Beutler E, Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 2002;99:15428-33
   PubMed Web of Science ®Google Scholar
• Kelly JW, Sawkar AR, Beutler E, Chemical chaperones and their effect upon the cellular activity of beta-glucosidase. WO2004037373, 2004
   Google Scholar
• Alfonso P, Pampin S, Estrada J, Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cell Mol Dis 2005;35:268-76
   PubMed Web of Science ®Google Scholar
• Yu ZQ, Sawkar AR, Whalen LJ, Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem 2007;50:94-100
   PubMed Web of Science ®Google Scholar
• Fan J-Q, Ishii S, Asano N. Method for increasing the activity of lysosomal enzymes. US20030119874, 2003
   Google Scholar
• Fan J-Q, Ishii S, Asano N. Method for increasing the activity of lysosomal enzymes. US20050113415, 2005
   Google Scholar
• Fan J-Q, Ishii S, Asano N. Method for increasing the activity of lysosomal enzymes. US20070021381, 2007
   Google Scholar
• Chang HH, Asano N, Ishii S, Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J 2006;273:4082-92
   PubMed Web of Science ®Google Scholar
• Steet RA, Chung S, Wustman B, The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci USA 2006;103:13813-18
   PubMed Web of Science ®Google Scholar
• Steet R, Chung S, Lee W-S, Selective actions of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol 2007;73:1376-83
   PubMed Web of Science ®Google Scholar
• Mugrage B, Tretyakov A. New methods for preparing isofagomine and its derivatives. US2008064559, 2008
   Google Scholar
• Mugrage B, Tretyakov A, Fuerst D, New methods for preparing isofagomine and its derivatives. WO2008144773, 2008
   Google Scholar
• Mugrage B, Sheth KA, Palling D, Rybcynski PJ. Tartrate salt of isofagomine and methods of use. WO2007140212, 2007
   Google Scholar
• Mugrage B, Sheth KA, Palling D, Rybcynski PJ. Tartrate salt of isofagomine and methods of use. US20090176830, 2009
   Google Scholar
• Khanna R, Benjamin ER, Pellegrino L, The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J 2010;277:1618-38
   PubMed Web of Science ®Google Scholar
• Wustman B. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes. WO2006133446, 2006
   Google Scholar
• Lockhart D. Treatment of Gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers. WO2008128106, 2008
   Google Scholar
• Lockhart D, Wustman B. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones. WO2008134628, 2008
   Google Scholar
• Safety study of AT2101 in adult patients with type 1 Gaucher disease currently receiving enzyme replacement therapy. NCT00433147
   Google Scholar
• A study to evaluate and characterize the effect of pharmacological chemicals on blood from patients with Gaucher disease. NCT00465062
   Google Scholar
• A long-term extension study of AT2101 in type 1 Gaucher patients. NCT00813865
   Google Scholar
• A study of oral AT2101 in treatment-naïve patients with Gaucher disease. NCT00446550
   Google Scholar
• Amicus Therapeutics. Available from: www.amicustherapeutics.com/clinicaltrials [Last accessed 11th February 2011]
   Google Scholar
• Fan J-Q, Zhu X, Sheth K. Hydroxy piperidine derivatives to treat Gaucher disease. WO2005046612, 2005
   Google Scholar
• Fan J-Q, Zhu X, Sheth K. Hydroxy piperidine derivatives to treat Gaucher disease. US20100189708, 2010
   Google Scholar
• Boyd R, Lee G. Methods for preventing and/or treating degenerative disorders of the central nervous system. WO2010118282, 2010
   Google Scholar
• Boyd R, Lee G. Methods for preventing and/or treating lysosomal storage disorders. WO2010118283, 2010
   Google Scholar
• Yu L, Ikeda K, Kato A, alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease. Bioorg Med Chem 2006;14:7736-44
   PubMed Web of Science ®Google Scholar
• Compain P, Martin OR, Boucheron C, Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease. ChemBioChem 2006;7:1356-9
   PubMed Web of Science ®Google Scholar
• Martin OR, Compain P, Boucheron C, Asano N. Novel compounds of the family of iminosugars, uses thereof for treating lysosomal diseases, and methods for preparing same. WO2006136714, 2006
   Google Scholar
• Fan JQ, Zhu X, Sheth K. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease. US20050137223, 2005
   Google Scholar
• Fan JQ, Zhu X, Sheth K. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease. WO2005046611, 2005
   Google Scholar
• Diaz-Perez VM, Garcia-Moreno MI, Ortiz Mellet C, Generalized anomeric effect in action: synthesis and evaluation of stable reducing indolizidine glycomimetics as glycosidase inhibitors. J Org Chem 2000;65:136-43
   PubMedGoogle Scholar
• Garcia-Moreno MI, Diaz-Perez P, Ortiz Mellet C, Garcia Fernandez JM. Castanospermine-trehazolin hybrids: a new family of glycomimetics with tuneable glycosidase inhibitory properties. Chem Commun 2002:848-9
   PubMedGoogle Scholar
• Garcia-Moreno MI, Diaz-Perez P, Ortiz Mellet C, Garcia Fernandez JM. Synthesis and evaluation of isourea-type glycomimetics related to the indolizidine and trehazolin glycosidase inhibitor families. J Org Chem 2003;68:8890-901
   PubMedGoogle Scholar
• Diaz-Perez P, Garcia-Moreno MI, Ortiz Mellet C, Garcia Fernandez JM. Synthesis and comparative glycosidase inhibitory properties of reducing castanospermine analogues. Eur J Org Chem 2005:2903-13
   Google Scholar
• Aguilar M, Diaz-Perez P, Garcia-Moreno MI, Synthesis and biological evaluation of guanidine-type iminosugars. J Org Chem 2008;73:1995-8
   PubMedGoogle Scholar
• Sanchez-Fernandez E, Risquez-Cuadro R, Aguilar-Moncayo M, Generalized anomeric effect in gem-diamines: stereoselective synthesis of alpha-N-linked disaccharide mimics. Org Lett 2009;11:3306-9
   PubMedGoogle Scholar
• Garcia Fernandez JM, Ortiz Mellet C, Garcia Moreno MI, Compounds promoting the activity of mutant glycosidases. WO2010046517, 2010
   Google Scholar
• Luan Z, Higaki K, Aguilar-Moncayo M, Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)-deoxynojirimycin. ChemBioChem 2009;10:2780-92
   PubMed Web of Science ®Google Scholar
• Ogawa S, Ashiura M, Uchida C, Synthesis of potent beta-D-glucocerebrosidase inhibitors: N-alkyl-beta-valienamines. Bioorg Med Chem Lett 1996;6:929-32
   Google Scholar
• Lin H, Sugimoto Y, Ohsaki Y, N-Octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta 2004;1689:219-28
   PubMedGoogle Scholar
• Luan Z, Li L, Ninomiya H, The pharmacological chaperone effect of N-octyl-beta-valienamine on human mutant acid beta-glucosidases. Blood Cell Mol Dis 2010;44:48-54
   PubMed Web of Science ®Google Scholar
• Matsuda J, Suzuki O, Oshima A, Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci USA 2003;100:15912-17
   PubMed Web of Science ®Google Scholar
• Llebaria Soldevilla A, Casas Brugulat J, Egido Gabas M, Ciclohexano hexasubstituido activador de la enzima beta-glucosidass, procedimiento de sintesis, composicion farmaceutica que lo contiene y sus aplicaciones. EP2289853, 2008
   Google Scholar
• Egido-Gabas M, Canals D, Casas J, Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease. ChemMedChem 2007;2:992-4
   PubMed Web of Science ®Google Scholar
• Mahuran DJ, Tropak MB, Buttner JD, Method for treating Gaucher disease. WO2009038695, 2009
   Google Scholar
• Maegawa GH, Tropak MB, Buttner JD, Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009;284:23502-16
   PubMed Web of Science ®Google Scholar
• Maegawa GH, Tropak M, Buttner J, Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem 2007;282:9150-61
   PubMed Web of Science ®Google Scholar
• Mahuran D, Tropak M, Withers S. Treatment of Tay Sachs or Sandhoff disease by enhancing hexosaminidase activity. WO2004103368, 2004
   Google Scholar
• A phase I study of pyrimethamine in patients with GM2 gangliosidosis. NCT00679744
   Google Scholar
• Mahuran DJ, Tropak MB, Buttner JD, Compositions and methods for enhancing enzyme activity in Gaucher GM1-gangliosidosis/Morquio B disease and Parkinson's disease. WO2009049421, 2009
   Google Scholar
• Mahuran DJ, Tropak MB, Buttner JD, Compositions and methods for enhancing enzyme activity in Gaucher GM1-gangliosidosis/Morquio B disease and parkinson's disease. WO2009049422, 2009
   Google Scholar
• Futerman A, Sussman JL, Silman I, Gaucher disease drugs and methods to identifying same. US20070166813, 2007
   Google Scholar
• Bultron G, Kacena K, Pearson D, The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis 2010;33:167-73
   PubMed Web of Science ®Google Scholar
• Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 2010;10:190-8
   PubMed Web of Science ®Google Scholar
• Sidransky E, Nalls MA, Aasly JO, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-61
   PubMed Web of Science ®Google Scholar
• Morello JP, Salahpour A, Laperriere A, Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000;105:887-95
   PubMed Web of Science ®Google Scholar
• Amaral MD. Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease. J Inherit Metab Dis 2006;29:477-87
   PubMed Web of Science ®Google Scholar
• Barral JM, Broadley SA, Schaffar G, Hartl FU. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 2004;15:17-29
   PubMed Web of Science ®Google Scholar
• Jones GW, Tuite MF. Chaperoning prions: the cellular machinery for propagating an infectious protein? Bioessays 2005;27:823-32
   PubMed Web of Science ®Google Scholar
• Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005;6:11-22
   PubMed Web of Science ®Google Scholar
• Luan Z, Higaki K, Aguilar-Moncayo M, A fluorescent sp2-iminosugar with pharmacological chaperone activity for Gaucher disease: synthesis and intracellular distribution studies. ChemBioChem 2010;11:2353-64
   Google Scholar
• Wang GN, Reinkensmeier G, Zhang SW, Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease. J Med Chem 2009;52:3146-9
   PubMedGoogle Scholar
• Kawamura A, Roach AG, Wilson FX, Treatment of protein folding disorders. WO2009066069, 2009
   Google Scholar
• Wilson FX, Nash RJ, Horne G, Treatment of lysosomal storage disorders and other proteostatic diseases. WO2010015816, 2010
   Google Scholar
• Wilson FX, Storer R, Kawamura A, Drug combination for the treatment of proteostatic diseases. WO2010116141, 2010
   Google Scholar
• Witte MD, Kallemeijn WW, Aten J, Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol 2010;6:907-13
   PubMed Web of Science ®Google Scholar
• Kornhaber GJ, Tropak MB, Maegawa GH, Isofagomine induced stabilization of glucocerebrosidase. ChemBioChem 2008;9:2643-9
   PubMedGoogle Scholar
• Tropak MB, Kornhaber GJ, Rigat BA, Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. ChemBioChem 2008;9:2650-62
   PubMed Web of Science ®Google Scholar
• Shen JS, Edwards NJ, Hong YB, Murray GJ. Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun 2008;369:1071-5
   PubMed Web of Science ®Google Scholar
• Flanagan JJ, Rossi B, Tang K, The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat 2009;30:1683-92
   PubMed Web of Science ®Google Scholar
• Marie I. Combined therapy of imiglucerase and miglustat in Gaucher disease with severe bone complications. Press Medicale 2009;38:2S68-70
   PubMedGoogle Scholar
• Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-98
   PubMed Web of Science ®Google Scholar
• Mu T-W, Ong DST, Wang Y-J, Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008;134:769-81
   PubMed Web of Science ®Google Scholar